The European Urological Scholarship Programme (EUSP) is proud to announce a new collaboration with the EAU Section of Andrological Urology (ESAU) and ReproUnion to encourage pioneering research on the effects of COVID-19 on urological patients. The EUSP, ESAU and ReproUnion are searching for two post-doc/PhD fellows to take part in one of the two projects […]
Urinary tract symptoms are a common complaint in patients with multiple sclerosis (MS) and comprise a great burden for this group of patients, affecting health-related quality of life. The quantification of such symptoms is not an easy task for both the clinician and patient and is mostly performed via the utilization of patient-reported outcome tools, […]
San Francisco, CA (UroToday.com) — The Prostate Cancer Foundation (PCF) and Movember announced two new Movember-PCF Challenge Awards. The awards, which total $2 million, are granted to teams at some of the world’s leading cancer research institutions to support cross-disciplinary pioneering research toward the goal of finding cures for prostate cancer. Of these funds, $792,000 […]
Coronavirus disease-19 (COVID-19) pandemic caused delays in definitive treatment of patients with prostate cancer. Beyond the immediate delay a backlog for future patients is expected. Such delays can lead to disease progression.
To analyze the effect of preoperative serum sodium and hemoglobin on oncologic outcomes in upper tract urothelial carcinoma (UTUC) based on a multi-center cohort from China and the United States (U.
Incidence of a second testicular tumor is higher in patients diagnosed with testicular cancer than in the general population. As incidence of unilateral germ cell cancer is increasing worldwide and most of these patients are cured, a growing number of patients at risk of developing a contralateral testis cancer is expected.
Metastatic renal cell carcinoma with sarcomatoid dedifferentiation (sRCC) is associated with poor survival outcomes. We aimed to analyze the efficacy and safety of immune checkpoint inhibitors (ICI) in patients with sRCC comparing clear-cell (sccRCC) to non-clear cell epithelial histology (snccRCC).
On the 15 November 2018, the Committee for Medicinal Products for Human Use adopted an extension to an existing indication for the use of nivolumab (Opdivo) in combination with ipilimumab (Yervoy) for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (RCC).
Nivolumab-ipilimumab has become the standard of care in the frontline setting for intermediate-/poor-risk metastatic renal cell carcinoma (mRCC). This regimen is associated with survival improvement but significant toxicity.
The purpose of the study was to develop an improved classifier for predicting biochemical recurrence (BCR) in clinically localized PCa patients after radical prostatectomy. Retrospective study including 122 PCa patients who attended our department between 2000 and 2007.
